-transparent.png){kind=logo}
Thirteen patients with primary and metastatic CNS tumors have been treated with methotrexate (MTX) using three different approaches: (a) high-dose MTX with leucovorin (LV) rescue; (b) high-dose MTX with carboxypeptidase (CPDG) rescue; and (c) intraventricular administration of low doses of MTX for extended periods (concentration X time [CXT]). Eleven patients had central nervous system (CNS) lymphoma (one primary, one patient had recurrent medulloblastoma, and another patient had metastatic breast carcinoma. All 13 patients received high-dose MTX-LV rescue, while 3 patients were subsequently given MTX-CPDG. One patient received MTX by all three modalities. In patients with CNS lymphomas, complete responses (45%) and partial responses (36%) produced CNS disease-free intervals ranging from 1 to 23+ months. Survival for the complete responders has thus far ranged from 2.5 to 35 months, while the partial responders survived from 3 to 5 months. Two patients failed to respond and survived 2.5 and 3 months. Responses were obtainable with high-dose MTX-CPDG in patients resistant to MTX-LV. One patient who became sensitized to CPDG subsequently responded to MTX by intraventricular CXT administration. Thus, MTX can be effectively administered to patients with CNS tumors by several different approaches.
H T Abelson, and
D W Kufe, and
A T Skarin, and
P Major, and
W Ensminger, and
G P Beardsley, and
G P Canellos
January 1994,
Medical and pediatric oncology,
H T Abelson, and
D W Kufe, and
A T Skarin, and
P Major, and
W Ensminger, and
G P Beardsley, and
G P Canellos
September 2004,
Clinical cancer research : an official journal of the American Association for Cancer Research,
H T Abelson, and
D W Kufe, and
A T Skarin, and
P Major, and
W Ensminger, and
G P Beardsley, and
G P Canellos
July 1977,
Cancer treatment reports,
H T Abelson, and
D W Kufe, and
A T Skarin, and
P Major, and
W Ensminger, and
G P Beardsley, and
G P Canellos
June 1989,
Arthritis and rheumatism,
H T Abelson, and
D W Kufe, and
A T Skarin, and
P Major, and
W Ensminger, and
G P Beardsley, and
G P Canellos
December 1978,
Cancer treatment reports,
H T Abelson, and
D W Kufe, and
A T Skarin, and
P Major, and
W Ensminger, and
G P Beardsley, and
G P Canellos
December 2005,
No to shinkei = Brain and nerve,
H T Abelson, and
D W Kufe, and
A T Skarin, and
P Major, and
W Ensminger, and
G P Beardsley, and
G P Canellos
January 2005,
Cancer chemotherapy and biological response modifiers,
H T Abelson, and
D W Kufe, and
A T Skarin, and
P Major, and
W Ensminger, and
G P Beardsley, and
G P Canellos
March 1987,
Clinics in laboratory medicine,
H T Abelson, and
D W Kufe, and
A T Skarin, and
P Major, and
W Ensminger, and
G P Beardsley, and
G P Canellos
October 2007,
Mayo Clinic proceedings,
H T Abelson, and
D W Kufe, and
A T Skarin, and
P Major, and
W Ensminger, and
G P Beardsley, and
G P Canellos
August 1995,
Seminars in veterinary medicine and surgery (small animal),
